

# Apigenin Attenuates Transverse Aortic Constriction-Induced Myocardial Hypertrophy: The Key Role of miR-185-5p/SREBP2-Mediated Autophagy [Letter]

Istianah Purnamasari, Yuyun Sri Wahyuni, Hernawati Basir

Department of Pharmacy, Faculty of Medicine and Health Science, Universitas Muhammadiyah Makassar, Makassar, South Sulawesi, Indonesia

Correspondence: Istianah Purnamasari, Department of Pharmacy, Faculty of Medicine and Health Science, Universitas Muhammadiyah Makassar, Makassar, South Sulawesi, Indonesia, Email [istianahpurnamasari@unismuh.ac.id](mailto:istianahpurnamasari@unismuh.ac.id)

## Dear editor

We have read the article by Yan et al entitled Apigenin Attenuates Transverse Aortic Constriction-Induced Myocardial Hypertrophy: The Key Role of miR-185-5p/SREBP2-Mediated Autophagy.<sup>1</sup> The purpose of this study was to clarify the apigenin anti-myocardial hypertrophy (MH) specific to the changes in miR-185-5p-mediated autophagy. Apigenin (4', 5, 7-trihydroxyflavone) is a natural flavonoid compound commonly found in vegetables and fruits and has been used traditionally for hypertension by locals in many countries.

Yan et al conducted research on transverse aortic constriction (TAC) in rats to induce Myocardial Hypertrophic symptoms. TAC is a widely used method to mimic cardiovascular disease in humans and to elucidate the fundamental signaling processes involved in the cardiac hypertrophic response and the development of heart failure. Other experimental models of heart failure, such as complete occlusion of the left anterior coronary artery (LAD) when compared with TAC, show that TAC provides a more reproducible model of cardiac hypertrophy and a more gradual time course in the development of heart failure.<sup>2</sup> They found that TAC surgery caused weight increase, structure damage, and collagen deposition in the hearts of model rats. While the addition of apigenin can improve cardiac function, attenuated cardiac hypertrophy which induced by TAC surgery.

Previously Gao et al, found that apigenin improves hypertension and cardiac hypertrophy in SHR which are associated with the down-regulation of NADPH oxidase-dependent ROS generation and inflammation in the PVN. Previously, Gao et al demonstrated that hypertension and cardiac hypertrophy in SHR can be improved using apigenin by down-regulating NADPH oxidase-dependent ROS production and inflammation in the PVN.<sup>3</sup> Moreover, the cardioprotective effect of apigenin was identified by detecting changes in miR-185-5p/SREBP2 axis. MicroRNA (miRNA) is a type of non-coding RNA that either inhibits RNA translation or induces the destruction of target mRNAs. Mostly, miRNAs alter cellular signaling by targeting multiple genes within the pathway. Specifically, miR-185 was consistently detected in four different cardiac hypertrophy signaling pathways and was highly expressed in the heart, brain, and kidney indicating that miR-185 may have a potential role in these organs. In the heart of pressure overload-induced cardiac hypertrophy models miR-185 is expressed differentially. Moreover, miR-185 has 22 high-score targets in the cardiac hypertrophy signaling pathway, as determined by cross-species target predictions.<sup>4</sup> Yan et al found that TAC induced the expression level of miR-185-5p and decreased the expression level of SREBP2, while the addition of apigenin reserved this effect.<sup>1</sup> Kim et al 2015 has found that miR-185 significantly inhibited cardiac hypertrophy signaling through numerous targets, making it a potential drug target for diseases such as heart failure.

We acknowledge and appreciate the findings obtained by this research. We agree that apigenin had anti-MH effects where they could increase the autophagy effect by inhibiting miR-185-5p and activating SREBP.

## Disclosure

All authors report no conflicts of interest in this communication.

## References

1. Yan N, Wang X, Xu Z, Zhong L, Yang J. Apigenin attenuates transverse aortic constriction-induced myocardial hypertrophy: The key role of miR-185-5p/SREBP2-mediated autophagy. *Drug Des Devel Ther.* 2024;18:3841–3851. doi:10.2147/DDDT.S464004
2. deAlmeida AC, van Oort RJ, Wehrens XH. Transverse aortic constriction in mice. *J visu exper.* 2010;2010(38):1729.
3. Gao HL, Yu XJ, Hu HB, et al. Apigenin improves hypertension and cardiac hypertrophy through modulating NADPH Oxidase-Dependent ROS generation and Cytokines in Hypothalamic paraventricular nucleus. *Cardiova Toxi.* 2021;21(9):721–736. doi:10.1007/s12012-021-09662-1
4. Kwon EJ, Hong SE, Song HK, Min CK, Kim DH. miR-185 plays an anti-hypertrophic role in the heart via multiple targets in the calcium-signaling pathways. *PLoS One.* 2015;10(3):e0122509. doi:10.1371/journal.pone.0122509

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Drug Design, Development and Therapy 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Drug Design, Development and Therapy editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Drug Design, Development and Therapy

Dovepress

**Publish your work in this journal**

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>

<https://doi.org/10.2147/DDDT.S498092>